Insider Selling: Intuitive Surgical, Inc. (NASDAQ:ISRG) VP Sells 810 Shares of Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) VP Fredrik Widman sold 810 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $573.78, for a total transaction of $464,761.80. Following the transaction, the vice president now directly owns 473 shares of the company’s stock, valued at approximately $271,397.94. This represents a 63.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Intuitive Surgical Stock Down 1.1 %

Shares of Intuitive Surgical stock traded down $6.17 during trading hours on Monday, hitting $566.98. 1,705,279 shares of the company’s stock traded hands, compared to its average volume of 1,732,928. Intuitive Surgical, Inc. has a twelve month low of $364.17 and a twelve month high of $616.00. The company has a market cap of $201.95 billion, a PE ratio of 88.45, a PEG ratio of 5.85 and a beta of 1.39. The stock has a 50 day simple moving average of $570.66 and a 200-day simple moving average of $530.08.

Analyst Ratings Changes

Several equities analysts recently commented on ISRG shares. Piper Sandler reaffirmed an “overweight” rating and set a $670.00 price target (up previously from $538.00) on shares of Intuitive Surgical in a research report on Friday, January 24th. Royal Bank of Canada upped their price objective on Intuitive Surgical from $611.00 to $641.00 in a report on Monday, January 27th. Wells Fargo & Company lifted their target price on Intuitive Surgical from $630.00 to $687.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Raymond James upped their price target on Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a research note on Friday, January 24th. Finally, JPMorgan Chase & Co. lifted their price objective on Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $613.10.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ISRG. Vanguard Group Inc. boosted its stake in shares of Intuitive Surgical by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 32,212,196 shares of the medical equipment provider’s stock valued at $16,813,478,000 after buying an additional 360,591 shares during the last quarter. State Street Corp raised its holdings in Intuitive Surgical by 1.4% in the third quarter. State Street Corp now owns 15,050,121 shares of the medical equipment provider’s stock valued at $7,393,673,000 after acquiring an additional 210,363 shares in the last quarter. FMR LLC raised its holdings in Intuitive Surgical by 8.3% in the third quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider’s stock valued at $5,389,765,000 after acquiring an additional 838,793 shares in the last quarter. Geode Capital Management LLC boosted its stake in Intuitive Surgical by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 7,756,727 shares of the medical equipment provider’s stock valued at $4,039,200,000 after acquiring an additional 243,802 shares during the last quarter. Finally, Fisher Asset Management LLC grew its holdings in Intuitive Surgical by 1.8% during the 4th quarter. Fisher Asset Management LLC now owns 4,868,869 shares of the medical equipment provider’s stock worth $2,541,356,000 after acquiring an additional 86,488 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.